Trial Profile

A Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Mar 2025 Planned End Date changed from 1 Jul 2025 to 1 Jan 2026.
13 Mar 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Jan 2026.
06 Jan 2025 According to a NMD Pharma media release, the company has three ongoing global clinical trials investigating NMD670 including a Phase 2 study in adults living with spinal muscular atrophy (SMA) type 3, a Phase 2b study in gMG patients, and this Phase 2 CMT study, with data readout(s) occurring from 2H/2025 through 1H/2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com